Given the lack of separation from sham on the primary endpoints in parts A and B, part C of the study was terminated early (2021)
Weight loss in turn improves blood pressure, lipid profile, insulin sensitivity, and systemic inflammatory markers, mechanisms that likely contribute to the 20% relative reduction in MACE observed in the SELECT trial despite the absence of diabetes in the enrolled population
The standard titration schedule for Wegovy involves gradual dose increases every four weeks, starting at 0.25 mg weekly and reaching the maintenance dose of 2.4 mg by week 17
The most optimal outcomes stem from a collaborative approach
It is classified as a potent antioxidant with demonstrated effects on lipid metabolism, insulin sensitivity, and inflammation in both animal and human studies
This may alleviate some burdens on healthcare systems and promote healthier communities